PHP182 Understanding Local Commissioning Decisions on New Pharmacotherapies In The Uk  by Singh, S & Purchase, J
 VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  A545
it is unlikely to be able to substantially reduce injectable medicines’ prescription 
without addressing the issue.
PHP180
THe CliniCal and eConomiC Burden of mediCaTion errors in THe 
Canadian aCuTe Care seTTing: a review of PuBlisHed sTudies
Baginska E
Becton Dickinson, Mississauga, ON, Canada
Objectives: Medication errors that occur in the acute care setting can lead to 
increased utilization of health care resources, especially when they cause tem-
porary or permanent patient harm. A pragmatic literature review was conducted 
to assess the clinical and economic impact of medication errors in Canadian 
hospitals. MethOds: A search of the MEDLINE database was conducted using the 
subject terms “medication error”, “preventable adverse drug event” and “Canada”. 
Studies were included if they described the frequency or cost of medication errors 
or preventable adverse drug events (pADEs) (defined as medication errors that 
cause patient harm), were conducted in a Canadian acute care setting, and were 
published in the last decade. Additional studies were selected from reference lists 
of identified studies. Studies were assessed for study design, setting, type of medi-
cations studied, and outcomes measured (event frequency, costs). Results: Eight 
studies were identified between 2004 and 2014. One study estimated the frequency 
of all pADEs at the national level using analysis of retrospective chart reviews 
(0.08% per admission). The remaining seven studies were conducted at individual 
institutions across Canada. Of these, three studies used chart review analysis to 
quantify the frequency of errors among all drug types (between 1.1% and 3.8% 
of all admissions), while four studies used chart review and direct observation 
to focus on quantifying the frequency of specific types of errors (dosing, label-
ling) for specific drug types (opioids, other IV medications). No studies assessed 
the cost of errors. cOnclusiOns: Results of studies at both the national and 
regional level demonstrate that medication errors pose a significant clinical bur-
den to patient care in Canadian acute care settings. Further research is needed to 
quantify the economic burden of these events to the health care system, in order 
to assist policy-makers and health administrators in prioritizing policies that 
support prevention efforts.
PHP181
u.s. Payer exPeCTaTions for reimBursemenT of Biosimilars
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Objectives: U.S. healthcare spending on high-cost biologics has escalated over 
the past decade. The Biologics Price Competition and Innovation Act allows for 
biosimilar products in the U.S., which will be lower-cost alternatives to reference 
biologics. This study explored payer attitudes to the reimbursement and adoption 
of biosimilars in the U.S. MethOds: Medical or pharmacy directors at managed 
care organizations (MCOs) were surveyed during April 2015 regarding their expec-
tations for biosimilar reimbursement. Results: Eligible respondents (n= 59) indi-
cate that MCOs expect biosimilars to offer a significant discount to the reference 
brand to secure reimbursement. A mean discount of 22–23% is considered adequate, 
while 29–30% is deemed necessary for preferential reimbursement to the reference 
brand. Rapid formulary inclusion of biosimilars is expected; 72% of respondents 
indicate formulary inclusion within 12 months of launch for the first entrant in 
a class. Widespread reimbursement of biosimilars in extrapolated indications is, 
however, uncertain, with only 29% of respondents reporting that their MCO would 
unconditionally reimburse a biosimilar under such circumstances. Payers expect 
to employ various strategies to promote biosimilar uptake, from favorable tiering to 
step edits; the most conducive strategies are expected for products with deep dis-
counts. Payers will also run educational campaigns for physicians. However, ≥ 63% of 
respondents expect their approach to be influenced by thought-leading physicians 
and medical associations. A large proportion of respondents expect “grandfather-
ing” (continuation of the reference brand in responsive/stable patients) to be per-
mitted, particularly when the biosimilar discount is modest. cOnclusiOns: U.S. 
payers will preferentially promote biosimilars over reference brands using various 
demand- and supply-side measures, provided that biosimilars meet their discount 
expectations and have clinical stakeholder buy-in. Payers clearly seek to realize the 
cost savings biosimilars offer; however, tendency to seek clinical stakeholder buy-
in, coupled with “grandfathering”, indicates some need for more robust evidence 
of cost-effectiveness.
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Objectives: To understand the trends and drivers of local decision-making by 
Clinical Commissioning Groups (CCGs), and how they may vary across localities, 
therapy areas, and by respective performance against key performance indicators 
(KPIs). MethOds: The MIMS website was searched to derive an exhaustive list 
of new pharmacotherapies between April 2013 and April 2015. This list was cross 
checked against all assessments conducted by the National Institute for Health 
and Care Excellence (NICE). The products that had been reviewed by NICE were 
subsequently excluded, given CCGs must implement any recommendation by NICE 
and hence does not demonstrate local decision making. Secondly, a representa-
tive sample of CCGs were selected across the regional locations of North, South, 
Midlands and East of England, and London (as defined by the NHS England regional 
team structure). A sample of 20 CCGs were shortlisted and their respective formu-
lary lists analysed to capture their commissioning decisions on the non-Nationally 
assessed pharmacotherapies. Finally, CCG commissioning decisions on the sample 
products was correlated against any local key performance indicators or priorities, 
the CCG Outcome Indicators, and their respective performance against them, to 
Objectives: Medication analysis (MA) and medication management (MM) are 
increasingly implemented in community pharmacies. However, little is known about 
the main intention of pharmacy owners to provide medication analysis in Germany. 
Thus, the objective of this study was to explore awareness of MA and MM and to 
predict the intention to provide MA. MethOds: Approximately 2,700 pharmacies 
listed in the database of the Bavarian Chamber of Pharmacists were invited via email 
to complete the web-based online survey (February/March 2015). The survey instru-
ment was designed to assess the constructs of attitude, perceived behavioral control, 
subjective norm and intention to provide MA, based on the theory of planned behav-
ior. Data were analyzed by using descriptive statistics. Linear regression models 
were used to predict the intention to provide MA. Results: A total of 295 phar-
macy owners completed the survey. More than half of the respondents (66.8%) rated 
themselves as familiar or very familiar with the term MA, with slightly more than 
half of the respondents (55.2%) offering MA. Overall, 70.9% of the respondents rated 
themselves as familiar or very familiar with the concept of MM, whereas only 25.1% 
stated to provide MM in their pharmacy. Perceived barriers included a lack of time 
and staff. The linear regression analysis revealed significant predictors of pharmacy 
owners’ intention to provide MA. These comprised the constructs of attitude, subjec-
tive norm and perceived behavioral control (p< 0.05), whereas gender and number of 
employees did not have a significant effect. cOnclusiOns: Findings suggest that 
community pharmacists are aware of the concepts of MA and MM. Attitude, subjec-
tive norm and perceived behavioral control were significant predictors of intention 
to provide MA. Strategies to improve the intention of community pharmacists to 
provide MA should focus on these predictors and the perceived barriers that impede 
the provision of MA in Germany.
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Objectives: Even though physician rating websites (PRWs) have become more 
important in recent years, little is known about the relationship between quality 
of care of physicians and patients’ online ratings. It still remains unclear whether 
these ratings are a reliable source for patients for choosing a physician. The aim 
of the study was to measure the association between structural and quality of 
care measures and online ratings in a German Integrated Healthcare Network 
(QuE). MethOds: Data from 65 QuE practices were collected and comprised 21 
indicators related to process quality (N= 10), structural information (N= 6), inter-
mediate outcomes (N= 2), costs (N= 2) and patient satisfaction (N= 1) for the year 
2012. We analyzed patients’ online ratings from two German PRWs (N= 1,179 and 
N= 991) over a three-year period (2011 to 2013). We applied the Spearman rank 
coefficient of correlation to measure the association between practice-related 
information and patient ratings. Results: For both PRWs, patient satisfaction 
results from offline surveys and the patients per doctor ratio in a practice were 
shown to be significantly associated with online ratings. Significant associations 
could be shown between online ratings and cost-related measures for medica-
tion, preventative examinations, and one diabetes type 2-related intermediate 
outcome measure on one PRW. Results from the second PRW showed significant 
associations with the number of patients per practice and the age of the physi-
cians, one cost-related measure for medication and four process-related quality 
measures. cOnclusiOns: Significant associations observed in this study varied 
across different PRWs. When choosing a doctor, patients interested in the satisfac-
tion of other patients with a physician might rely on online ratings. Even though 
our results indicate associations with some diabetes and asthma measures, but 
not with coronary heart disease measures, there is still insufficient evidence to 
draw strong conclusions. Findings may be weakened due to the limited number 
of practices considered.
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Objectives: Overuse of injections is a common problem in many low-income 
and middle income countries. While cultural factors and attitudes of both physi-
cians and patients are important factors, physicians’ financial intensives may 
play an important role in overprescribing of injections. This study was designed 
to assess the effects of providing injection services in physicians’ ambulatory 
offices on prescribing injectable medicines. MethOds: This cross-sectional 
study was conducted in Tehran in 2012 -2013and included a random sample of 
general physicians, pediatricians and infectious disease specialists. We collected 
data on the provision of injection services in or in proximity of physician offices, 
and obtained data from physicians’ prescriptions in the previous three-month 
period. We analyzed the data using ANOVA, Student’s t-test and linear regres-
sion methods. Results: We obtained complete data from 465 of 600 sampled 
physicians. Overall 41.9% of prescriptions contained injectable medicines. 75% of 
physicians offered injection services in their offices. Male physicians and general 
physicians were more likely to offer the services, and more likely to prescribe 
injectables. We observed a clear linear relationship between the injection ser-
vice working hours and the proportion of prescriptions containing injectables 
(p-value< 0.001). cOnclusiOns: Providing injection service in the office was 
directly linked with the proportion of prescriptions containing injectables. While 
provision of injection services may provide a direct financial benefit to physicians, 
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ment recommendation by performing the Pearson’s Chi-squared test, Kolmogorov-
Smirnov test, and Wilcoxon rank sum test. Results: In total, 53 pharmacoeconomic 
evaluations were included in this study. Of these, 16 concerned orphan drugs, while 
37 evaluated high cost- drugs. Of the 53 pharmaceutical compounds evaluated in 
this study, 39 (73.6%) received a positive reimbursement advice, 11 (20.8%) received 
a negative reimbursement advice, and 3 drugs were not assessed for reimburse-
ment through either the outpatient reimbursement system nor the intramural 
high cost reimbursement system (5.7%). In total, 277 deviations from the phar-
macoeconomic guidelines were observed, but no single item was found to have a 
statistically significant effect on the reimbursement recommendation. In contrast 
to drug safety and cost-effectiveness outcomes, both drug efficacy and therapeutic 
value showed to have statistically significant impact on the reimbursement deci-
sion. cOnclusiOns: In The Netherlands, drug efficacy and therapeutic value can 
be considered as essential criteria in the reimbursement decision of orphan and 
expensive pharmaceuticals, resulting in a reimbursement system being centered 
on clinical value. Even though cost-effectiveness does not have a significant impact 
on the decision, compliance in the reimbursement dossiers by manufacturers to 
the Dutch Guidelines for Pharmacoeconomic research can be further improved.
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Objectives: The diagnosis-related group (DRG) based reimbursement system has 
been voluntarily applied to inpatients with seven diseases in the Korean national 
health insurance since 2002, and was mandatory for all health-care institutions 
from July 1, 2013. The main purpose of this study was to evaluate the perfor-
mance of DRG-based reimbursement in health care expenditure and to propose 
alternative policies. MethOds: A non-equivalent control group pretest-posttest 
design with a difference-in-difference approach was adopted to compare changes 
in medical service utilization and physician’s behavior between DRG-based 
reimbursement(experimental group) and fee-for-service reimbursement(control 
group). Seven diseases to which DRG-based reimbursement was applied included 
tonsillectomy, cataract surgery, appendectomy, herniotomy, hemorrhoidectomy, 
hysterectomy, and Caesarean section. The panel data were produced from year 
2004~2011 medical claims database of the National Health Insurance, which covered 
a total of 1,119,028 cases per year. Results: From 2004 to 2011, surgical operations 
in institution reimbursed by DRG have been significantly increased more than those 
in institutions reimbursed by fee-for-service. The results showed that the DRG-based 
payment has reduced the length of stay in seven diseases, while it has changed phy-
sician’s behavior to charge DRG-code upward and shift medical tests and expensive 
antibiotics from inpatients to outpatients because DRG was applied to inpatient 
only. The DRG-based payment in seven diseases has consistently increased medi-
cal expenditure as well as medication expenses more than fee-for-service, partly 
due to no global budget in the Korean national health insurance. cOnclusiOns: 
Challenges and future issues to expand the DRG-based reimbursement system to 
all diseases for inpatients should be considered such as monitoring service quality, 
strategic plans to control physicians’ behavior, limiting the number of DRG clas-
sifications, and the introduction of global budgeting.
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Objectives: Beginning in 2014, the Affordable Care Act requires new health 
plans to cover essential health benefits (EHB), including pharmaceutical products, 
according to the state level benchmark plans. The objectives of this analysis were 
to understand state level variations in design of plans, access to drugs and likely 
impact on patient choice and health outcomes. MethOds: Benchmark plans for 
the top five states (i.e., FL, IL, NY, TX and CA), covering ~116 million lives, were 
obtained from the CMS. For each plan, the categories, classes and number of cov-
ered drugs was collected and pooled into one database. Analysis was conducted at 
the entire population level, state-level and for top classes of drugs. The comments 
from patient groups were reviewed to understand the impact of EHB on patient 
choice and health outcomes. Results: Benchmark plans for the top five states 
provide coverage of 4215 drugs belonging to 158 classes as defined by USP. While 
four states (FL, IL, NY and TX) had a similar number of covered drugs (median of 
892 drugs), CA had a significantly lower number of covered drugs, amounting to 
28% less than the other four states. On average, 10% of the drugs were in the class 
called “No USP Class”, highlighting the limitation of CMS designated USP clas-
sification system for the new plans. In CA, FL, IL, NY and TX there were 18, 7, 8, 11 
and 8 classes, respectively, for which only 1 was covered. In CA, top 8 classes were 
identified for which patients had a 75% lower choice than other states, and these 
included indications such as Anti-Diabetics and Pain medications. cOnclusiOns: 
Review of new benchmark plans shows some states can have a significantly lower 
patient choice of therapies. There is a need for new policy measures to ensure that 
all patients have equal access to new treatments.
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Objectives: International Reference Pricing (IRP) is a key cost-containment tool 
for health care payers across the world. IRP may apply either fixed or flexible 
determine any trends and drivers of local decision-making. Results: As expected, 
there was variation across CCGs in funding decisions. However, there was only a 
limited correlation between funding decisions and CCG priorities or performance. 
It became evident that there were no strong discernible trends or drivers for local 
funding decisions on these products. cOnclusiOns: Unlike the national level 
assessments undertaken by NICE, the drivers of local formulary decisions on new 
pharmacotherapies are difficult to establish and vary across CCG, making it dif-
ficult for pharmaceutical companies to obtain access for their medicines using a 
“one size fits all” approach. Thus, pharmaceutical companies need to engage more 
closely with CCGs to better understand their needs (including beyond-the-pill) and 
demonstrate the ‘localised’ value of pharmacotherapies.
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Objectives: Since the introduction of the AMNOG in January 2011, an early benefit 
assessment by the German G-BA is required for all new drugs in Germany. Objective 
of our study was to identify any predictors of G-BA decisions. MethOds: All G-BA 
decisions up to 04/2015 were analyzed; basic characteristics of each drug as well as 
of each decision were documented. A multivariate ordinal regression analysis, using 
given additional benefit classification (ranging from 1 for major additional benefit 
to 5 for no additional benefit) as dependent variable, was conducted. Results: 130 
completed G-BA assessment procedures were evaluated. Within these, G-BA deci-
sions were as follows: 16.9% of the drugs received considerable additional benefit 
(for at least one patient subgroup), 23.1% received a minor additional benefit, 10.0% 
received a non-quantifiable additional benefit, and 50.0% received no additional 
benefit. Due to the specifics of German value assessment, orphan drugs auto-
matically receive an additional benefit, but 39.1% of the assessed drugs received a 
non-quantifiable additional benefit (lowest possible assessment). Our multivariate 
regression analysis showed that the strongest predictors for an above-average ben-
efit ranking were proven advantages in mortality (p< 0.001) or morbidity (p= 0.001). 
Additionally, products for use in malignant (p= 0.013) or infectious diseases (p< 0.001) 
as well as orphan treatments (p= 0.027) were more likely to reach a better benefit 
rating. Furthermore, any evidence of a favorable safety profile of a treatment is 
associated with a better ranking (p= 0.10). cOnclusiOns: Key factors for positive 
G-BA decisions seem to be a proven superiority in mortality or morbidity against 
the standard treatment as defined by the German G-BA. However, this is difficult 
to prove in specific chronic disease areas, especially if surrogate outcomes are not 
widely accepted. This may explain why, for example, 80% of the assessed diabetes 
drugs did not receive any additional benefit in Germany.
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Objectives: In Germany, the reimbursement and pricing of innovative in-patient 
drugs and devices is managed through the NUB application process. These applica-
tions are submitted by the hospital stakeholder and are approved or rejected by the 
Institute for the Hospital Remuneration System (InEK ). The objective of this research 
was to assess the NUB trends in Germany in 2012-2014. MethOds: We developed 
a database of NUB approvals and rejections based on the Institute for the Hospital 
Remuneration System’s (InEK )’s reports. All information was extracted into Excel 
format. The following data was extracted: product name, indication, year of submis-
sion, number of NUB applications submitted, status score, type of evidence available 
and lack of evidence for NUB rejection. Additionally, the number of re-applications 
and re-rejections were also analyzed. Results: In 2013 and 2014, a total of 21264 
and 25634 NUB applications were submitted for 612 and 613 medical products, 
respectively. Of these applications in 2013 and 2014, 10% and 16% were approved 
for NUB (as Status 1) and 82% and 75% were rejected (as Status 2), respectively. In 
2014, the median number of hospital applications for NUBs with Status 1 and Status 
2 were 37 and 3, demonstrating the importance of hospital participation for seek-
ing NUB approval. Among approved NUBs, 37% of the applications were for drugs 
and 63% were for devices. Interestingly, the median NUB hospital applications for 
approved drugs was 192, while for devices, the median was 9 applications. In 2014, 
447 NUB applications for products were re-submitted, of which 5 were approved and 
the remaining were re-rejected. The evidence requirements analysis suggests the 
need for hospital focused economic data. cOnclusiOns: The NUB process plays 
a critical role in market access for in-patient drugs and devices. For approval, two 
key components are: hospital focused economic evidence and provider stakeholder 
involvement.
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Objectives: The aim of this study is to (i) review the methodological quality of 
pharmacoeconomic evaluations of orphan and expensive drugs that applied for 
reimbursement in The Netherlands, and (ii) explore essential criteria in the reim-
bursement recommendations made by The Dutch National Healthcare Institute 
(ZINL). MethOds: Data were extracted from pharmacoeconomic reports published 
by ZINL between 1 January 2006 and 31 December 2013 using a data extraction 
form. Compliance to pharmacoeconomic guidelines was determined by evaluat-
ing deviations in the pharmacoeconomic reports from the list of provided items in 
the guidelines. Multiple variables (i.e. drug safety, efficacy, therapeutic value, and 
cost-effectiveness) were investigated regarding their influence on the reimburse-
